Sorrento therapeutics

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

Beleggen met ongekend lage tarieven?
Aandelen BE/NL €2+0,03% / VS €0,50+$0,004 p/st
Kernselectie: Geen kosten turbo's, ETF's en fondsen
DEGIRO: meer informatie / rekening openen


MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 277
Lid geworden op: 28 mar 2019 23:43
waarderingen: 137
Contacteer:

Re: Sorrento therapeutics

Bericht door MONEYCAT »

ancaoli schreef:
20 feb 2021 09:32
MONEYCAT schreef:
20 feb 2021 00:43
ancaoli schreef:
19 feb 2021 23:45
Yipie! Er is een 10K filing maar weet nog niet meer
Van Yahoo Message Board ...

more from 10k filing - Revenues. Revenues were $40.0 million for the year ended December 31, 2020, as compared to $31.4 million for the year ended December 31, 2019.

Revenue in our Sorrento Therapeutics segment increased from $10.4 million to $13.7 million for the year ended December 31, 2020 compared to the prior year and was primarily attributed to higher contract manufacturing service revenues.

Revenue in our Scilex segment increased from $21.0 million to $26.3 million for the year ended December 31, 2020 compared to the prior year due to increased product sales of ZTlido.

:clap: :up:
Bedankt maar daar wordt ik nu echt niet warm van. Revenues betekenen momenteel niet veel. Vooral vooruitgang met testen en goedkeuringen zijn nu belangrijk. Daarnaast ook graag update over NK, Acea etc ... 200 blz WE lectuur :?
Uiteraard primeert nu PR’s , FDA UEA, allerlei goedkeuringen, akkoorden, producten op de markt krijgen en dan volgen de resultaten wel van zelf...tenzij een of andere kandidaat overnemer het moment gekomen voelt ... :think:





ancaoli
Forum elite
Forum elite
Berichten: 2040
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1086
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Yahoo posters doen hun huiswerk waarvoor dank. Hierbij des post van Paul;

Paul4 hours ago
Some key takeaways from the earnings report folks ☕️☕️

Antibody Clinical Development

We currently focus our research efforts primarily in the identification and isolation of human antibody drug candidates and further characterize these antibody candidates in in vitro and in vivo functional testing. Due to our limited financial resources, we intend to actively seek product development and commercialization partners from the biopharmaceutical industry to help us advance the clinical development of select product candidates.

(Key words or sentences-We intend to ACTIVELY SEEK product development and commercialization partners)

Marketing and Sales

With the exception of our subsidiary, Scilex Holding, we currently do not have any sales capabilities. We intend to license to, or enter into strategic alliances with, larger companies in the biopharmaceutical businesses or use the services of contract sales organizations (“CROs”), which are equipped to, market and/or sell our products, if any, through their well-developed marketing and sales teams and distribution networks. We intend to license some or all of our worldwide patent rights to more than one third party to achieve the fullest development, marketing and distribution of any products we develop.

(Key words or sentences-We intend to LICENSE to, or enter into strategic ALLIANCES with larger companies in the biotech business or use the the service of contract sales organizations (CROs)

(I have to point out some terrific posters who routinely ‘bring it’ when they post. Chuck, MikeD44, and Don. In this case Chuck who routinely points out that Sorrento would be better served and trials, etc... faster paced with a top notch CRO. Chuck on point like always)

Manufacturing and Raw Materials

We currently manufacture the majority of our preclinical and clinical materials in-house, and use contract manufacturers for the manufacture of some of our product candidates. We may or may not manufacture the products we develop, if any. As of December 31, 2020, our ZTlido product is manufactured by ITOCHU CHEMICAL FRONTIER Corporation. Our internal manufacturing and contract manufacturers are subject to extensive governmental regulation. Regulatory authorities in our markets require that pharmaceutical products be manufactured, packaged and labeled in conformity with cGMPs. We have established a quality control and quality assurance program, which includes a set of standard operating procedures and specifications designed to ensure that our products are manufactured in accordance with cGMPs, and other applicable domestic and foreign regulations.

(One of the key takeaways I thought of immediately, and MikeD44 explained in a terrific post several weeks ago in regards to STIX. Sorrento is highly unlikely to use FortuneBio to manufacture STIX. Think a big manufacturer in the US and EUROPE. My thoughts, my guess is that in countries where there is less stringent rules or regulations they might use FortuneBio, but I find that highly unlikely except for someplace like maybe China because of FortuneBio’s location)
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

ancaoli
Forum elite
Forum elite
Berichten: 2040
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1086
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

En dit is zijn mening ivm BO:

I would say in regards to any possible BO of Sorrento that the price would be extremely high, and I don’t see it at this time. The big pharma’s and biotechs are looking at biotechs in the the small to medium price range.

Because of stiff competition and well funded biotechs the pharma’s are already having to shell out larger sums of money to lock down deals.

The hedge funds, institutional investors, and pharma’s have all tried to various degrees to hold down Sorrento for their own reasons. Ji has handled the situation more then anyone could have expected, and managed to move trials forward and made major negotiations/deals that have Sorrento well positioned for many years to come.

My thought is partnerships for 2021. 2022 onwards they will be in a much better position of strength to negotiate any supposed BO. Final note. For those who think Sorrento won’t have the financial wherewithal to move trials ahead. You haven’t been paying attention.
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

ancaoli
Forum elite
Forum elite
Berichten: 2040
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1086
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

En Don (ook van Yahoo) merkte het volgende op:

Don46 minutes ago
What do you think about this analysis by chxal? Preventing hostile takeover attempts?
"Pre-emptive Measures in 10K....

What no one is talking about is Sorrento has now filed in their 10K that there are anti-takeover measures being readied to prevent a hostile takeover! They "probably" have received offers for the business since last May, and now they are at a point where those offers are going to result in the acquirer(s) trying to buy shares to gain a majority position and get a board seat to influence a sales transaction OR try to oust current SRNE management (read: Ji).

This would be done by a proxy fight with the acquirer trying to convince the rest of the shareholders to vote for an acquisition.
They could also put on the proxy to vote Ji out as CEO.

The good news with this 10K filing, is that the anti-takeover, preferred shares issuing, possible poison pill ARE IN THERE! Normally an acquiring company goes to the company's Board of Directors to try and negotiate an outcome -- like buying the company for $x' amount per share. If these negotiations are not successful for the acquirer, their strategy changes from "nice guy - let's make a deal" to "hostile" whereby shares are acquired, alliances formed with other large shareholders, and a proxy war ensues with the acquirer trying to "team up" with the existing shareholders, other than mgmt, to "win" the company.

The fact that Ji added the anti-takeover provisions, preferred shares, poison pill language going forward PROBABLY means an offer, big position, partnership, merger, etc. will be announced or LEAKED (by the acquirer) very soon. This is the hidden gem of the 10K that no one is talking about, but in my view is the reason the price spiked after the 10K was released. The UPS story could have had something to do with it, but I think it was the 10K that did it, and Wall Street will probably pick up on this on Monday, to say "Sorrento is in play".
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

ancaoli
Forum elite
Forum elite
Berichten: 2040
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1086
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Nog eentje van Don:

Don10 minutes ago
There could be 8 EUA's this year! Covi-Stix will be the first.
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection
6. Abivirtinib ARDS prevention
7. Covi-MSC Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail
Each of these EUA's could be accompanied by Operation Warp Speed grants and multi-billion dollar international sales. Additionally there could multi-billion dollar worldwide marketing partnerships. Dr.Ji says there is "humungous" interest from Mexico, Brazil and Europe.

And we can expect a dozen or more cancer IND's this year. Those ready to go will be chosen from...
* 20 ADC's(Antibody Drug Conjugates)targets
* 12 ADNAB (Mayo Clinic Albumin Bound platform)targets
* 12 DAR-T targets with the first entering the clinic soon. These will go after hard to treat indications (MM,lymphoma,glioma,liver and pancreatic)
* a second generation oncolytic virus

Funding? EUA grants and sales. Huge profits from Celularity and ImmunityBio investments. PSS lawsuit settlement. Partnership up-front, milestone and royalty payments. The company has an embarrassment of valuable resources!
MONEYCAT liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

believer
Forum elite
Forum elite
Berichten: 5239
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4487
Contacteer:

Re: Sorrento therapeutics

Bericht door believer »


believer
Forum elite
Forum elite
Berichten: 5239
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4487
Contacteer:

Re: Sorrento therapeutics

Bericht door believer »

Grote positie JP Morgan
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
alwaysright liked last!

MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 277
Lid geworden op: 28 mar 2019 23:43
waarderingen: 137
Contacteer:

Re: Sorrento therapeutics

Bericht door MONEYCAT »

believer schreef:
21 feb 2021 13:28
Grote positie JP Morgan
Waaaw Dit wil toch allemaal wat zeggen...JPM dat zijn toch echt geen sukkelaars!👍
believer liked last!

alwaysright
Forum actieveling
Forum actieveling
Berichten: 981
Lid geworden op: 10 mei 2013 19:25
waarderingen: 420
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

Het is maar hoe je het bekijkt,bouwen ze positie op omdat ze er gewoon in geloven of doen ze dit om deze aandelen gelijk uit te lenen aan hedgefunds.
Ze zou kunnen denken dat ze van beide walletjes willen eten,immers,uitlenen voor beperkte tijd,rente vangen,en bij echt nieuws hebben ze de aandelen in ieder geval al in bezit.Wat wel apart is is dat de short posities zeker een half jaat niet zo "laag"
zijn geweest...22%
Ik ben echt benieuwd wat de komende weken gaan brengen,het stukje van Motley Fool is ook niet echt nieuws,wat deze man zegt wisten we al.
MONEYCAT liked last!

believer
Forum elite
Forum elite
Berichten: 5239
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4487
Contacteer:

Re: Sorrento therapeutics

Bericht door believer »

MONEYCAT schreef:
21 feb 2021 14:08
believer schreef:
21 feb 2021 13:28
Grote positie JP Morgan
Waaaw Dit wil toch allemaal wat zeggen...JPM dat zijn toch echt geen sukkelaars!👍
Denk dat we morgen zeer hoog kunnen openen..

Het nieuws van Hong Kong,JP Morgan met hun grote positie,steeds meer analisten die hun enorme pijplijn inzien en positieve artikels neerpennen...


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie